An Expanded Access Program for the non-invasive detection of clear cell renal cell carcinoma in patients with renal masses utilizing 89Zirconium-labelled girentuximab (89Zr-DFO-girentuximab)

This study has not yet been registered on ClinicalTrials.gov, which is currently a pre-requisite for display of detailed eligibility criteria.

• If you need assistance with ClinicalTrials.gov registration for an oncology study, please contact the Jonsson Comprehensive Cancer Center's Office of Regulatory Compliance.
• If you need assistance with ClinicalTrials.gov registration for a non-oncology study, please contact the Office of Regulatory Affairs.